14 results
PRE 14A
TPST
Tempest Therapeutics Inc
22 Apr 22
Preliminary proxy
4:01pm
of $250,000 in connection with Millendo’s Change in Control.
Health and Welfare Benefits; Perquisites
Our Named Executive Officers are eligible … perquisites or personal benefits to our named executive officers, except in limited circumstances, and we did not provide any perquisites or personal
8-K
EX-2.1
TPST
Tempest Therapeutics Inc
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
, fringe benefits, perquisites, change in control benefits, deferred compensation, bonuses, stock options, stock purchase, phantom stock, stock appreciation
425
EX-2.1
8885e6
29 Mar 21
Business combination disclosure
7:27am
DEFM14A
gu26u eq0
6 Nov 18
Proxy related to merger
12:00am
424B3
q14a2q 8f
5 Nov 18
Prospectus supplement
3:51pm
S-4/A
wnhttxoh
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
8-K
EX-2.1
hhtcua hfp5
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
425
EX-2.1
wfayvwo6qw
9 Aug 18
Business combination disclosure
5:17pm
- Prev
- 1
- Next